CIA
RPRX icon

Caledonia Investments (Australia)’s Royalty Pharma RPRX Stock Holding History

Caledonia Investments (Australia)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$344M Sell
7,168,399
-208,639
-3% -$9.14M 10% 5
2025
Q4 		$285M Sell
7,377,038
-170,571
-2% -$6.5M 5.46% 5
2025
Q3 		$266M Buy
7,547,609
+1,102,880
+17% +$39.9M 4.33% 5
2025
Q2 		$232M Buy
6,444,729
+1,330,162
+26% +$44.1M 3.69% 5
2025
Q1 		$159M Buy
+5,114,567
New +$162M 2.59% 7

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Caledonia Investments (Australia)'s RPRX Position: Q1 2026 in Review

Caledonia Investments (Australia) reduced its Royalty Pharma (RPRX) stake by 2.8% in Q1 2026, selling an estimated $9.14M and leaving 7,168,399 shares worth $344M. The position accounts for 10% of the portfolio, ranked #5.

Caledonia Investments (Australia) first reported a position in RPRX in Q1 2025 and has held it in 5 quarters since. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Caledonia Investments (Australia) held 7,168,399 shares of Royalty Pharma worth $344M as of Q1 2026.
  • Caledonia Investments (Australia) sold 208,639 Royalty Pharma shares in Q1 2026, an estimated $9.14M.
  • Royalty Pharma made up 10% of Caledonia Investments (Australia)'s portfolio in Q1 2026, its #5 holding.
  • Caledonia Investments (Australia) first reported a position in Royalty Pharma in Q1 2025 and has held it in 5 quarters since.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Caledonia Investments (Australia)'s 13F filing for Q1 2026, filed 15 May 2026.